Astellas Pharma and Drais Pharmaceuticals have entered into a partnership to develop and commercialize ASP7147, a bombesin BB2 receptor antagonist for the treatment of irritable bowel syndrome with diarrhea. Astellas will transfer ownership of the drug to Seldar Pharma, Inc., a virtual company that will be operated by Drais’ executive team. Astellas and Drais entered into a similar agreement in April to advance ASP3291 through another virtual company, Telsar, which will also be operated by Drais...